Lexicon Pharmaceuticals | LXRX - Interest Expense On Debt


Lexicon Pharmaceuticals reported $2.03M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Abbott USD 68M 26M Mar/2026
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Akebia Therapeutics 4.83M 359.32M Dec/2025
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
AstraZeneca USD 484M 181M Dec/2025
BioMarin Pharmaceutical USD 2.78M 199K Dec/2025
Coherus Biosciences USD 2.25M 76K Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Esperion Therapeutics USD 22.64M 585K Dec/2025
Halozyme Therapeutics USD 4.91M 615K Dec/2025
Illumina USD 25M 0 Sep/2025
Insmed USD 20.6M 217K Dec/2025
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
J&J USD 43M 25M Mar/2026
Lexicon Pharmaceuticals USD 2.03M 124K Dec/2025
MacroGenics USD 3.34M 2.54M Sep/2025
MannKind USD 13.87M 6.54M Dec/2025
Merck USD 412M 85M Dec/2025
Moderna USD 12.14B 12.13B Sep/2025
Novartis USD 304M 23M Dec/2025
PTC Therapeutics USD 50.58M 2.59B Dec/2025
Puma Biotechnology USD 3.37M 11K Jun/2024
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Thermo Fisher Scientific USD 365M 18M Dec/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
United Therapeutics USD 3.1M 100K Dec/2025
Vanda Pharmaceuticals 601.14M 23.61M Sep/2025